| Literature DB >> 36200221 |
Marko Celicanin1,2, Adrian Paul Harrison3, Jack Kvistgaard Olsen2, Lise Korbo1, Annemette Løkkegård1, Charlotte Bjerg Petersen1, Bente Danneskiold-Samsøe2, Hartwig Roman Siebner1,3,4, Tihomir Ilic5, Else Marie Bartels1,2.
Abstract
Bioimpedance (mfBIA) non-invasively assesses cellular muscle health. Our aim was to explore whether mfBIA captures abnormal cellular muscle health in patients with Parkinson's Disease (PD) and how such changes are modulated with the use of Parkinson's medication. In patients with PD (n = 20) mfBIA measurements were made of biceps brachii, triceps, and extensor carpi radialis longus muscles of the more affected arm whilst at rest, using a mobile mfBIA device (IMPEDIMED, Australia). mfBIA and assessment of motor symptoms were performed in a pragmatic off-medication state, as well as one and 3 h after oral intake of 200 mg levodopa. Age and sex-matched healthy subjects (HC; n = 20) served as controls. PD and HC mfBIA parameters were compared by applying an unpaired two-tailed adjusted t-test and ANOVA with Tukey's correction for multiple comparisons (p ≤ 0.05). The PD group consisted of 13 men (71 ± 17 years) and 7 women (65 ± 7 years). Independent of medication, internal (Ri ) and external resistance (Re ) were found to be significantly higher, and membrane capacitance (Mc) significantly lower, in m.biceps brachii in PD subjects compared to HC. Center frequency (fc) was significantly higher in m.biceps brachii of PD subjects in the "medication-off" state. There was no difference between PD and HC in mfBIA parameters in the measured extensor muscles. The upper limb flexor muscle shows a difference in mfBIA parameters in PD compared to HC. mfBIA may be useful in the diagnosis and assessment of PD patients and is objective, non-invasive, reliable, and easy to use.Entities:
Keywords: Parkinson's disease; bioimpedance; multi-frequency; muscle tonus; muscles
Mesh:
Substances:
Year: 2022 PMID: 36200221 PMCID: PMC9535347 DOI: 10.14814/phy2.15465
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Statistically significant mfBIA parameters given by p‐values for male healthy controls (HC) versus male Parkinson's subjects (PD) of m. biceps at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Males | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | Ri
| Ri
| Ri
|
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
Statistically significant mfBIA parameters given by p‐values for female healthy controls (HC) versus female Parkinson's subjects (PD) of m. biceps at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Females | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | Ri
| Ri
| Ri
|
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
Statistically significant mfBIA parameters given by p‐values for male healthy controls (HC) versus male Parkinson's subjects (PD) of m. triceps at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Males | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | Ri
| Re
| Ri
|
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
Statistically significant mfBIA parameters given by p‐values for female healthy controls (HC) versus female Parkinson's subjects (PD) of m. triceps at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Females | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | NS | NS | NS |
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
Statistically significant mfBIA parameters given by p‐values for male healthy controls (HC) versus male Parkinson's subjects (PD) of m. extensor carpi radialis longus at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Males | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | NS | NS | NS |
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
Statistically significant mfBIA parameters given by p‐values for female healthy controls (HC) versus female Parkinson's subjects (PD) of m. extensor carpi radialis longus at three different time points; PD0 = defined as pragmatic off = free of medicine for 3 × T1/2 (12 h), and both PD1 at 1 and PD3 at 3 h following medicine intake
| Females | HC | PD0 | PD1 | PD3 |
|---|---|---|---|---|
| HC | NS | NS | NS | NS |
| PD0 | — | NS | NS | NS |
| PD1 | — | — | NS | NS |
| PD3 | — | — | — | NS |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | ||||||||
| Time 0 | 91.1 ± 31.1 | 90.5 ± 31.3 | 51.1 ± 9.6 | 6.3 ± 3.8 | 313.6 ± 187.8 | 105.3 ± 33.4 | 8.8 ± 2.9 | 10.5 ± 7.6 |
| Time 1 | 88.4 ± 36.4 | 87.9 ± 36.6 | 58.7 ± 36.8 | 6.6 ± 3.6 | 291.9 ± 219.5 | 103.1 ± 38.6 | 8.9 ± 2.9 | 11.5 ± 7.4 |
| Time 3 | 80.9 ± 27.8 | 80.2 ± 27.9 | 54.2 ± 29.6 | 7.3 ± 3.6 | 235.2 ± 146.0 | 95.7 ± 30.9 | 9.4 ± 3.0 | 12.4 ± 7.1 |
| Women | ||||||||
| Time 0 | 128.5 ± 42.0 | 128.2 ± 42.1 | 71.9 ± 27.8 | 3.9 ± 2.1 | 638.0 ± 415.7 | 140.6 ± 42.0 | 7.8 ± 2.1 | 4.5 ± 3.4 |
| Time 1 | 123.1 ± 37.6 | 122.8 ± 37.8 | 64.7 ± 10.7 | 4.1 ± 1.6 | 503.5 ± 276.1 | 136.4 ± 38.8 | 8.0 ± 1.1 | 4.9 ± 2.7 |
| Time 3 | 131.3 ± 43.9 | 131.0 ± 44.0 | 59.8 ± 25.3 | 3.9 ± 2.2 | 597.8 ± 342.0 | 145.8 ± 46.6 | 7.8 ± 2.4 | 5.2 ± 3.1 |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | 39.0 ± 4.6 | 38.4 ± 4.5 | 87.1 ± 19.3 | 9.8 ± 1.3 | 55.7 ± 7.5 | 45.9 ± 6.3 | 6.7 ± 1.4 | 18.9 ± 4.6 |
| Women | 44.9 ± 3.4 | 44.3 ± 3.3 | 90.3 ± 16.9 | 9.6 ± 2.0 | 69.5 ± 14.3 | 52.2 ± 4.6 | 7.5 ± 1.7 | 15.3 ± 4.4 |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | ||||||||
| Time 0 | 95.8 ± 34.6 | 95.4 ± 34.8 | 50.1 ± 18.6 | 5.0 ± 2.8 | 406.4 ± 255.1 | 108.2 ± 36.6 | 7.2 ± 1.9 | 9.4 ± 6.3 |
| Time 1 | 97.0 ± 38.4 | 96.7 ± 38.6 | 57.4 ± 15.6 | 5.2 ± 2.6 | 467.6 ± 468.1 | 108.5 ± 38.8 | 7.5 ± 2.4 | 8.1 ± 5.0 |
| Time 3 | 91.8 ± 34.1 | 91.4 ± 34.3 | 52.0 ± 18.4 | 4.9 ± 3.4 | 451.5 ± 299.0 | 102.6 ± 35.8 | 6.6 ± 2.0 | 9.0 ± 7.0 |
| Women | ||||||||
| Time 0 | 119.0 ± 23.9 | 118.7 ± 23.8 | 64.7 ± 21.3 | 3.6 ± 2.1 | 547.6 ± 228.0 | 132.4 ± 25.9 | 7.5 ± 4.3 | 4.8 ± 3.0 |
| Time 1 | 125.1 ± 38.6 | 124.8 ± 38.7 | 80.6 ± 29.5 | 4.0 ± 2.5 | 623.6 ± 429.3 | 137.4 ± 38.6 | 7.8 ± 3.7 | 4.5 ± 4.2 |
| Time 3 | 127.3 ± 48.9 | 127.1 ± 49.0 | 70.2 ± 27.3 | 2.9 ± 1.8 | 785.6 ± 484.1 | 137.2 ± 49.9 | 5.7 ± 2.1 | 4.0 ± 3. |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | 66.9 ± 15.7 | 66.4 ± 15.8 | 45.7 ± 15.2 | 7.1 ± 2.4 | 201.8 ± 113.4 | 79.5 ± 16.9 | 7.9 ± 2.4 | 16.1 ± 8.7 |
| Women | 104.7 ± 17.3 | 104.5 ± 17.3 | 78.6 ± 27.0 | 3.5 ± 0.7 | 446.0 ± 111.7 | 114.6 ± 17.8 | 6.3 ± 0.9 | 4.3 ± 2.1 |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | ||||||||
| Time 0 | 56.2 ± 16.8 | 55.4 ± 16.9 | 53.0 ± 8.8 | 9.8 ± 3.0 | 113.0 ± 75.1 | 69.0 ± 19.2 | 9.2 ± 2.7 | 19.5 ± 6.8 |
| Time 1 | 48.3 ± 11.8 | 47.5 ± 12.0 | 59.7 ± 12.6 | 10.6 ± 3.0 | 85.1 ± 47.5 | 59.5 ± 13.8 | 8.5 ± 1.9 | 21.2 ± 6.7 |
| Time 3 | 50.7 ± 11.0 | 49.9 ± 11.0 | 49.6 ± 7.4 | 10.5 ± 2.5 | 88.8 ± 38.6 | 63.8 ± 13.2 | 9.1 ± 2.1 | 23.1 ± 6.5 |
| Women | ||||||||
| Time 0 | 77.1 ± 12.0 | 76.5 ± 12.3 | 73.2 ± 21.5 | 6.8 ± 3.3 | 224.1 ± 138.2 | 88.9 ± 9.5 | 8.6 ± 3.2 | 9.3 ± 5.1 |
| Time 1 | 72.7 ± 9.2 | 72.1 ± 9.4 | 64.6 ± 15.1 | 6.9 ± 3.6 | 217.6 ± 140.0 | 84.7 ± 10.0 | 8.4 ± 4.2 | 10.2 ± 4.7 |
| Time 3 | 72.3 ± 11.3 | 63.9 ± 27.2 | 69.3 ± 35.0 | 7.4 ± 3.4 | 190.0 ± 118.6 | 85.6 ± 11.7 | 8.9 ± 3.8 | 11.6 ± 6.3 |
|
|
| Fc | PA | Ri | Re | Xc | Mc | |
|---|---|---|---|---|---|---|---|---|
| Men | 44.8 ± 11.5 | 43.8 ± 11.5 | 58.9 ± 16.7 | 11.9 ± 2.9 | 68.7 ± 45.5 | 56.7 ± 15.1 | 8.9 ± 2.6 | 25.9 ± 9.9 |
| Women | 67.1 ± 17.0 | 66.6 ± 17.0 | 63.8 ± 21.1 | 6.6 ± 1.6 | 167.8 ± 80.5 | 78.0 ± 18.6 | 7.5 ± 1.6 | 13.0 ± 7.9 |